MedTrace Logo

Evaluation of Fidaxomicin in the Treatment of Clostridium Difficile Infection (CDI)

NCT04070352 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2024-05-17

No results posted yet for this study

Summary

This is a single center collection of discarded biological samples and electronic medical review (EMR) data on patients who are hospitalized with clostridium difficile infections and treated with Fidaxomicin

Conditions

  • Clostridium Difficile Infection (CDI)

Interventions

DRUG

Fidaxomicin

patients who are receiving fidaxomicin are enrolled into the study, blood is obtained for analysis, EMR and outcome data collected regarding their CDI

Sponsors & Collaborators

Principal Investigators

  • Cornelius Clancy, MD · UPMC and PITT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-01
Primary Completion
2023-05-01
Completion
2023-05-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04070352 on ClinicalTrials.gov